Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder
Crossref DOI link: https://doi.org/10.1007/s00192-018-3662-y
Published Online: 2018-04-29
Published Print: 2018-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Abdelrahman, Abdelmageed
Text and Data Mining valid from 2018-04-29
Article History
Received: 16 April 2018
Accepted: 19 April 2018
First Online: 29 April 2018
Compliance with ethical standards
:
: None.